Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Roche

Bruised Roche Wins Another UK Perjeta Round With Price Cut

In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.

United Kingdom Cancer

Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree

The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.

Sales & Earnings Cancer

Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD

The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.

 

Neurology Clinical Trials

Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access

Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.

China Rare Diseases
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register